Abstract
The role of HLA antibodies in SCT has drawn increasing attention because of the significantly increased number of patients who receive HLA-mismatched SCT, including cord blood transplantation, haploidentical SCT and unrelated SCT. Technical advancements in the methods of HLA Ab testing have realized rapid, accurate and objective identification, as well as quantification of specific HLA antibodies. Recent clinical studies have suggested that the presence of donor-specific HLA antibodies (DSA) in patients is associated with graft failure in HLA-mismatched SCT when the above-listed stem cell sources are used and results in different impacts. Of note, most of the ‘HLA-matched’ unrelated SCT actually involve HLA mismatches in HLA-DP and the presence of antibodies against this locus has been reported to be associated with graft failure. Thus, HLA Ab should be examined as a work-up for all patients who undergo SCT from ‘alternative donors.’ The simplest route for preventing HLA Ab-mediated graft failure in Ab-positive patients is to avoid donors who possess the target Ag of HLA antibodies. If SCT from such donors must be performed, treatment for DSA before SCT may improve the chances of successful donor engraftment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hod E, Schwartz J . Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348–360.
Middelburg RA, van Stein D, Briet E, van der Bom JG . The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48: 2167–2176.
Reil A, Keller-Stanislawski B, Gunay S, Bux J . Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313–317.
Keller-Stanislawski B, Reil A, Gunay S, Funk MB . Frequency and severity of transfusion-related acute lung injury—German haemovigilance data (2006–2007). Vox Sang 2010; 98: 70–77.
Shaz BH, Stowell SR, Hillyer CD . Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011; 117: 1463–1471.
Barge AJ, Johnson G, Witherspoon R, Torok-Storb B . Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 1477–1480.
Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.
Patel R, Terasaki PI . Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735–739.
Gebel HM, Bray RA, Nickerson P . Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2003; 3: 1488–1500.
Terasaki PI, Cai J . Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377–383.
Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754–1761.
Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012; 27: 1231–1238.
Maslanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J . Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang 2007; 92: 247–249.
Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS . Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008; 48: 2549–2558.
Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825–1835.
Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824–828.
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861–1869.
van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A . HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003; 43: 765–771.
Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333–339.
Sparrow RL, Williams N . The pattern of HLA-DR and HLA-DQ antigen expression on clonable subpopulations of human myeloid progenitor cells. Blood 1986; 67: 379–384.
Piacibello W, Aglietta M, Stacchini A, Spinelli P, Salvetti L, Kerim S et al. Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. Leuk Res 1987; 11: 285–290.
Ottmann OG, Nocka KH, Moore MA, Pelus LM . Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells. Leukemia 1988; 2: 677–686.
Aglietta M, Piacibello W, Stacchini A, Dezza L, Sanavio F, Malavasi F et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Res 1986; 46 (Part 1): 1783–1787.
Amatruda 3rd TT, Bohman R, Ranyard J, Koeffler HP . Pattern of expression of HLA-DR and HLA-DQ antigens and mRNA in myeloid differentiation. Blood 1987; 69: 1225–1236.
Diedrichs-Mohring M, Epplen JT, Schendel DJ . Enhanced expression of HLA-class II molecules on activated human T lymphocytes following treatment with tumor necrosis factor alpha. Hum Immunol 1991; 31: 286–292.
Cai J, Terasaki PI, Mao Q, Pham T, El-Awar N, Lee JH et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947–2954.
Rodey GE, Fuller TC . Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7: 229–267.
Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA . Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272–280.
Piazza A, Poggi E, Ozzella G, Borrelli L, Monaco PI, Scornajenghi A et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques. Transplantation 2006; 81: 1298–1305.
Maruya E, Sasaki N, El-Awar N, Akaza T, Kitawaki J, Saji H et al. Immunogenic HLA class I epitopes identified by humoral response to pregnancies. Clin Transpl 2008, 215–227.
El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clin Transpl 2008, 199–214.
El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844–853.
Alberu J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC . A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl Immunol 2007; 18: 166–171.
Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J . Natural″ human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111–1115.
Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C . Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226–230.
Nagata S, Okano S, Yonemitsu Y, Nakagawa K, Tomita Y, Yoshikai Y et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006; 82: 689–698.
Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611–3619.
Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307–1315.
Storb R . B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood 2009; 113: 1205.
Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb HJ, Lerner KG et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974; 112: 1508–1516.
Weiden PL, Storb R, Slichter S, Warren RP, Sale GE . Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1976; 117: 143–150.
Gutman JA, McKinney SK, Pereira S, Warnock SL, Smith AG, Woolfrey AE et al. Prospective monitoring for alloimmunization in cord blood transplantation: ″virtual crossmatch″ can be used to demonstrate donor-directed antibodies. Transplantation 2009; 87: 415–418.
Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K . The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008; 48: 791–793.
Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116: 2839–2846.
Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011.
Brunstein CG, Noreen H, Defor TE, Maurer D, Miller JS, Wagner JE . Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011; 17: 1704–1708.
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019–1024.
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 47: 508–515.
Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851–2858.
Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200–4206.
Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177–1185.
Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923–1930.
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.
Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704–2708.
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P et al. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957–5964.
Kataoka K, Yamamoto G, Nannya Y, Yoshimi A, Okada S, Asai T et al. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. Bone Marrow Transplant 2008; 42: 129–130.
Uchiyama M, Ikeda T . Successful engraftment following umbilical cord blood transplantation for patients with HLA antibody with or without corresponding HLA in the transplanted cord blood. Bone Marrow Transplant 2010; 45: 199–200.
Maruta A, Fukawa H, Kanamori H, Harano H, Noguchi T, Kodama F et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant 1991; 7: 397–400.
Pollack MS, Ririe D . Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens. Hum Immunol 2004; 65: 245–247.
Costa LJ, Moussa O, Bray RA, Stuart RK . Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol 2010; 151: 94–96.
Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005; 36: 555–556.
Raghavan R, Jeroudi A, Achkar K, Gaber AO, Patel SJ, Abdellatif A . Bortezomib in kidney transplantation. J Transplant 2010; 2010: Article ID 698594.
Stegall MD, Gloor JM . Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8–10.
Knezevic-Maramica I, Kruskall MS . Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460–1480.
Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.
Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008; 36: 1–8.
Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265–2272.
Terasaki PI, Ozawa M, Castro R . Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408–415.
Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapec risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114: 4293–4299.
Lapierre V, Auperin A, Tayebi H, Chabod J, Saas P, Michalet M et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002; 100: 1484–1489.
Nakazawa Y, Saito S, Hasegawa Y, Yanagisawa R, Sakashita K, Kamijo T et al. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia. Transfusion 2007; 47: 326–334.
Hatakeyama N, Hori T, Yamamoto M, Inazawa N, Iesato K, Miyazaki T et al. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother. Pediatr Transplant 2011; 15: E177–E182.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yoshihara, S., Taniguchi, K., Ogawa, H. et al. The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?. Bone Marrow Transplant 47, 1499–1506 (2012). https://doi.org/10.1038/bmt.2011.249
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.249
Keywords
This article is cited by
-
PET assessment of acute gastrointestinal graft versus host disease
Bone Marrow Transplantation (2023)
-
Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation
Blood Cancer Journal (2019)
-
Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor
Bone Marrow Transplantation (2019)
-
Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions
Bone Marrow Transplantation (2018)
-
Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation
Bone Marrow Transplantation (2017)